These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 8554144)

  • 1. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver.
    Vitola JV; Delbeke D; Sandler MP; Campbell MG; Powers TA; Wright JK; Chapman WC; Pinson CW
    Am J Surg; 1996 Jan; 171(1):21-6. PubMed ID: 8554144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging recurrent metastatic colorectal carcinoma with PET.
    Delbeke D; Vitola JV; Sandler MP; Arildsen RC; Powers TA; Wright JK; Chapman WC; Pinson CW
    J Nucl Med; 1997 Aug; 38(8):1196-201. PubMed ID: 9255148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors.
    Böhm B; Voth M; Geoghegan J; Hellfritzsch H; Petrovich A; Scheele J; Gottschild D
    J Cancer Res Clin Oncol; 2004 May; 130(5):266-72. PubMed ID: 14767761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
    Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
    Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.
    Boykin KN; Zibari GB; Lilien DL; McMillan RW; Aultman DF; McDonald JC
    Am Surg; 1999 Dec; 65(12):1183-5. PubMed ID: 10597072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.
    Abdel-Nabi H; Doerr RJ; Lamonica DM; Cronin VR; Galantowicz PJ; Carbone GM; Spaulding MB
    Radiology; 1998 Mar; 206(3):755-60. PubMed ID: 9494497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study.
    Ruers TJ; Langenhoff BS; Neeleman N; Jager GJ; Strijk S; Wobbes T; Corstens FH; Oyen WJ
    J Clin Oncol; 2002 Jan; 20(2):388-95. PubMed ID: 11786565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization.
    Vitola JV; Delbeke D; Meranze SG; Mazer MJ; Pinson CW
    Cancer; 1996 Nov; 78(10):2216-22. PubMed ID: 8918417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT?
    Ramos E; Valls C; Martinez L; Lladó L; Torras J; Ruiz S; Gamez C; Serrano T; Fabregat J; Rafecas A
    Ann Surg Oncol; 2011 Sep; 18(9):2654-61. PubMed ID: 21431987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
    Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
    Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?
    Selzner M; Hany TF; Wildbrett P; McCormack L; Kadry Z; Clavien PA
    Ann Surg; 2004 Dec; 240(6):1027-34; discussion 1035-6. PubMed ID: 15570208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?
    Adie S; Yip C; Chu F; Morris DL
    ANZ J Surg; 2009 May; 79(5):358-61. PubMed ID: 19566517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
    Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
    Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of whole-body positron emission tomography with [18F]fluorodeoxyglucose in recurrent colorectal cancer.
    Beets G; Penninckx F; Schiepers C; Filez L; Mortelmans L; Kerremans R; Aerts R; De Roo M
    Br J Surg; 1994 Nov; 81(11):1666-70. PubMed ID: 7827902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.
    Zubeldia JM; Bednarczyk EM; Baker JG; Nabi HA
    Cancer Biother Radiopharm; 2005 Aug; 20(4):450-6. PubMed ID: 16114993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of positron emission tomography with fluorine-18-deoxyglucose in identifying colorectal cancer metastases to liver.
    Zhuang H; Sinha P; Pourdehnad M; Duarte PS; Yamamoto AJ; Alavi A
    Nucl Med Commun; 2000 Sep; 21(9):793-8. PubMed ID: 11065150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
    J Clin Oncol; 1996 Mar; 14(3):700-8. PubMed ID: 8622014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.